Richard Conway RichardPAConway
4 years ago
Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN
Dr. John Cush RheumNow
4 years ago
Prolonging the Controversy of Hydroxychloroquine
Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 that addressed the topic of HCQ and cardiovascular safety.
https://t.co/J6sVzYJkUZ https://t.co/dBZmtwQ927
Mrinalini Dey DrMiniDey
4 years ago
My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK
#axspa #spondyloarthritis #arthritis #qualityoflife
Watch it here👇🏼
https://t.co/MEQ4wkFxrx
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ
Mrinalini Dey DrMiniDey
4 years ago
A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental gymnastics and stress of ensuring I make all the sessions and meetings on time! 😂
⏰UK colleagues- time difference for #ACR21 will be +5️hours from tomorrow!
@RheumNow https://t.co/wl7ij3vyOU
Symplur Hashtags healthhashtags
4 years ago
Top Influencers of #acr21: @ACRheum @rheum_cat @RheumNow @CreakyJoints @DoctorYasmin @KDAO2011 More 📊 https://t.co/vyMAwjKbqC
Dr. Antoni Chan synovialjoints
4 years ago
There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as well as high specificity of RF and CCP for ICI-arthritis. Prospective evaluation of RF/CCP pre-treatment may be useful @RheumNow #ACR21 Abst#0440 https://t.co/P7L7pL1iuV
Janet Pope Janetbirdope
4 years ago
Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do about Class V renal, many class III, IV LNdon’t go into sustained remission, cases of new onset LN in pts with #Belimumab ?more/less than expected, which drug to use @RheumNow #ACR21 https://t.co/tWbw79dE7d
swethaann23 swethaann23
4 years ago
Torgutalp et al.
⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort
⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression.
Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Robert B Chao, MD doctorRBC
4 years ago
IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?
⬆️IL-22 in AxSpA vs. controls
⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP
Abs#385
#ACR21
@RheumNow https://t.co/hNtStAluJH
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for recurrent pericarditis was 7.9 weeks! During this time, >94% pts discontinued steroid and/or colchicine either sequentially or concurrently @RheumNow https://t.co/ofi3Jtm6j6 https://t.co/b6PnFw4gUN
Mrinalini Dey DrMiniDey
4 years ago
Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts.
👉~1300 patients
👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia
#ACR21 Abs#0284 @RheumNow
https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha


Poster Hall